Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.

Disclosed herein are methods for the production of mutant bacteriophages with altered host range. Additionally, disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

The invention relates to a bactericide composition based on bacteriophages for the control of black plague in plants or parts thereof, preferably walnuts, a preparation method and application. The invention provides methods for the isolation, propagation and application of bacteriophages against phytopathogens affecting trees/plants that are of commercial interest for their fruit, flowers etc., for the prevention, treatment or reduction of signs, in particular, for Xanthomonas A. pv juglandis in walnuts.

Disclosed herein are compositions, methods, kits and systems for rapid detection of microorganisms using a reproduction-deficient indicator bacteriophage. The specificity of such reproduction-deficient indicator bacteriophage for binding and infecting particular microorganisms of interest allows targeted and sensitive detection of a microorganism of interest.

The current disclosure provides protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing. The disclosed methods allow mapping of antibody epitopes and determination of changes in residues of a protein that abolish binding of the protein to a candidate binding molecule.

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.